You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 56 No. 5, May 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (23)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Immunologic Disorders
 •Multiple Sclerosis/ Demyelinating Disease
 •Alert me on articles by topic

HLA Class II Susceptibility to Multiple Sclerosis Among Ashkenazi and Non-Ashkenazi Jews

Oh Joong Kwon, PhD; Arnon Karni, MD; Shoshana Israel, PhD; Chaim Brautbar, PhD; Avraham Amar, PhD; Zeev Meiner, MD; Oded Abramsky, MD, PhD; Dimitrios Karussis, MD, PhD

Arch Neurol. 1999;56:555-560.

Objective  To look for HLA class II alleles and haplotypes conferring susceptibility to multiple sclerosis (MS) in the Jewish population of Israel.

Design  Population-based cohort of clinically definite patients with MS tested prospectively over 7 years.

Setting  Referral center in a neurology clinic at a university hospital in the greater Jerusalem area in Israel.

Patients  A total of 162 consecutive patients with clinically definite MS from the 2 main ethnic Jewish groups in Israel: 104 Ashkenazi (80 with a relapsing remitting or secondary progressive and 24 with a primary chronic progressive course of the disease) and 58 non-Ashkenazi (36 with a relapsing remitting or secondary progressive course and 22 with a primary chronic progressive course of the disease), matched with 132 Ashkenazi and 120 non-Ashkenazi healthy controls.

Main Outcome Measures  The relationship between the various HLA class II alleles and haplotypes and MS, as defined by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization, among the Ashkenazi and the non-Ashkenazi Jewish sections and with respect to the different clinical courses of the disease.

Results  The haplotype DRB1*1501, DQA1*0102, DQB1*0602 was found to be associated with MS among both Ashkenazi and non-Ashkenazi patients (P<.001 and P=.04, respectively). Among the non-Ashkenazi patients, a new association of haplotypes DRB1*1303, DQA1*05, and DQB1*0301with MS was detected (P=.03). The MS susceptibility alleles, DRB1*1501, DQA1*0102, and DQB1*0602 , were found in association with the Ashkenazi patients (P<.001, P=.02, and P=.01, respectively); DRB1*1501 and DRB1*1303 were more frequently observed among the non-Ashkenazi patients (P=.03, P=.04, respectively). On subdivision of the patients into clinical subgroups, associations of DRB1*0801, DQA1*0102, DQA1*0401, and DQB1*0602 with primary chronic progressive MS among the Ashkenazi patients were evident (P=.03, P=.04, P=.04 and P=.05, respectively), whereas DRB1*1501, DRB1*03011, and DQB1*0602 were associated with relapsing remitting or secondary progressive among the non-Ashkenazi patients (P=.05, P=.05, and P=.03, respectively).

Conclusions  This study, unlike previous ones, is the first to show a significant association between HLA class II alleles and MS in the Jewish population. The association with the HLA-DR2–related haplotype is similar to that among non-Jewish white patients with MS. Moreover, our data support the possibility that DRB1*1501 is the susceptibility allele responsible for the association between this haplotype and MS in the Jewish population. Our study also underscores differences in HLA profiles between Ashkenazi and non-Ashkenazi patients, and between the different clinical courses of the disease. The latter may indicate that the clinical courses of MS are influenced by the genetic background.


From the Tissue Typing Unit and the Lautenberg Center for General and Tumor Immunology (Drs Kwon, Israel, Brautbar, and Amar), and the Department of Neurology (Drs Karni, Meiner, Abramsky, and Karussis), Hadassah University Hospital, Hebrew University Hadassah Medical School, Jerusalem, Israel.


RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(5):634-636.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

HLA-DR15 Haplotype and Multiple Sclerosis: A HuGE Review
Schmidt et al.
Am J Epidemiol 2007;165:1097-1109.
ABSTRACT | FULL TEXT  

Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis
Barcellos et al.
Hum Mol Genet 2006;15:2813-2824.
ABSTRACT | FULL TEXT  

The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DR{beta}1 chain is associated with the clinical course of multiple sclerosis
Greer and Pender
J. Neurol. Neurosurg. Psychiatry 2005;76:656-662.
ABSTRACT | FULL TEXT  

HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis
Khare et al.
Int Immunol 2003;15:535-546.
ABSTRACT | FULL TEXT  

Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia
Marrosu et al.
Hum Mol Genet 2001;10:2907-2916.
ABSTRACT | FULL TEXT  

The HLA-DR13 haplotype is associated with ""benign"" multiple sclerosis in northeast Italy
Perini et al.
Neurology 2001;57:158-159.
ABSTRACT | FULL TEXT  

Evidence for the genetic role of human leukocyte antigens in low frequency DRBI*1501 multiple sclerosis patients in Israel
Karni et al.
Mult Scler 1999;5:410-415.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.